Literature DB >> 7584607

Recent advances in the metabolism of cannabinoids.

I Yamamoto1, K Watanabe, S Narimatsu, H Yoshimura.   

Abstract

This review describes recent advances in the metabolism of cannabinoids. Cannabidiol was metabolized to cannabielsoin, 6 beta-hydroxymethyl-delta 9-tetrahydrocannabinol and an oxepine derivative through epoxide intermediates by hepatic microsomal enzymes containing cytochrome P450 of animals. Cannabidiol inactivated cytochrome P450 UT-2 (CYP2C11) not equal to in male rats and a member of 3A subfamily in mouse liver. These inactivations may be very important because serious drug-drug interactions will occur in the case that cannabidiol is co-administered with drugs which are metabolized mainly by the enzyme system containing these P450 isozymes. A member of cytochrome P450 belonging to 2C subfamily was the major isozymes responsible for the cannabinoid metabolism in many experimental animals and that of 3A subfamily made some contribution to the metabolism of cannabinoids by human hepatic microsomes. Microsomal aldehyde oxygenase, a particular isozyme of cytochrome P450 catalyzing the oxidation of 11-oxo-tetrahydrocannabinol to tetrahydrocannabinol-11-oic acid, was found for the first time by the authors. Cytochrome P450 MUT-2 (CYP2C29) is the major isozyme responsible for the microsomal aldehyde oxygenase activity in mouse hepatic microsomes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7584607     DOI: 10.1016/1357-2725(95)00043-o

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  11 in total

1.  Case report: adverse effects of taking tricyclic antidepressants and smoking marijuana.

Authors:  V Mannion
Journal:  Can Fam Physician       Date:  1999-11       Impact factor: 3.275

2.  Cross-talk of cannabinoid and endocannabinoid metabolism is mediated via human cardiac CYP2J2.

Authors:  William R Arnold; Austin T Weigle; Aditi Das
Journal:  J Inorg Biochem       Date:  2018-04-07       Impact factor: 4.155

Review 3.  Drug interactions with cisapride: clinical implications.

Authors:  E L Michalets; C R Williams
Journal:  Clin Pharmacokinet       Date:  2000-07       Impact factor: 6.447

4.  Exposure to a high-fat diet decreases sensitivity to Δ9-tetrahydrocannabinol-induced motor effects in female rats.

Authors:  Jenny L Wiley; Amanda R Jones; M Jerry Wright
Journal:  Neuropharmacology       Date:  2010-09-17       Impact factor: 5.250

Review 5.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

6.  Cannabidiol As a Putative Novel Therapy for Diabetic Retinopathy: A Postulated Mechanism of Action as an Entry Point for Biomarker-Guided Clinical Development.

Authors:  Gi Liou; Ab El-Remessy; As Ibrahim; Rb Caldwell; Ym Khalifa; A Gunes; Jj Nussbaum
Journal:  Curr Pharmacogenomics Person Med       Date:  2009-09

Review 7.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Gonadal hormone modulation of ∆9-tetrahydrocannabinol-induced antinociception and metabolism in female versus male rats.

Authors:  R M Craft; A E Haas; J L Wiley; Z Yu; B H Clowers
Journal:  Pharmacol Biochem Behav       Date:  2016-09-24       Impact factor: 3.533

9.  Harm reduction--the cannabis paradox.

Authors:  Robert Melamede
Journal:  Harm Reduct J       Date:  2005-09-22

10.  Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs.

Authors:  Lauri-Jo Gamble; Jordyn M Boesch; Christopher W Frye; Wayne S Schwark; Sabine Mann; Lisa Wolfe; Holly Brown; Erin S Berthelsen; Joseph J Wakshlag
Journal:  Front Vet Sci       Date:  2018-07-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.